Nitric Oxide Nasal Spray for COVID-19 to Be Distributed to India and Other Asia Markets

SaNOtize and Glenmark Pharmaceuticals announced on August 2, 2021 an exclusive long-term strategic partnership to manufacture, market, and distribute SaNOtize’s nitric oxide nasal spray (NONS) for COVID-19 treatment to India and other Asian markets, including Singapore, Malaysia Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste, and Vietnam.

NONS were found to be a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms in SaNOtize’s March 2021 clinical trials.

NONS is designed to kill the COVID-19 virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide, which has proven anti-microbial properties and a direct effect on SARS-CoV-2.

The Subject Expert Committee of India’s Central Drugs Standard Control Organisation recommended a Phase III clinical trial for NONS to be conducted in Indian patients in the coming weeks. The Phase III trial is expected to be completed by Q4 2021, followed by a commercial launch.

Source: Businesswire, Glenmark Pharmaceuticals, SaNOtize